Research programme: beta-L-dideoxyadenosine prodrugs - Idenix
Latest Information Update: 23 May 2006
Price :
$50 *
At a glance
- Originator CNRS; Idenix Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 23 May 2006 No development reported - Preclinical for HIV infections treatment in France (unspecified route)
- 23 May 2006 No development reported - Preclinical for HIV infections treatment in USA (unspecified route)
- 09 May 2003 Novartis Pharma AG has acquired a majority equity interest in Idenix